GSK’s Blenrep Hit By Trial Failure, Raising Questions About Its Future In The Myeloma Market

Phase III Study Misses Endpoint

 
• By Andrew McConaghie
  
new gsk logo and hq
DREAMM-3's failure does not bode well for further readouts in earlier myeloma therapy, and could even see Blenrep removed from the market. • Source: GSK
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D